Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-RESPONSE-AHF: Dapagliflozin in Acute Heart Failure
NCT05406505Phase 3Completed
- Sponsor
- Mansoura University
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in dyspnea Visual Analogue Scale score at Day 4. Started Apr 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NCT05406505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406505.